Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia

1998499 citationsJournal Article

Authors

William E. Evans · University of Tennessee at Knoxville

Mary V. Relling · American Association of Colleges of Pharmacy

John H. Rodman · University of Tennessee at Knoxville

William R. Crom · American Association of Colleges of Pharmacy

James M. Boyett · St. Jude Children's Research Hospital

Ching‐Hon Pui · University of Tennessee at Knoxville

Abstract

Adjusting the dose of methotrexate to account for the patient's ability to clear the drug can improve the outcome in children with B-lineage acute lymphoblastic leukemia.

Topics & Keywords

Acute Lymphoblastic Leukemia research Pharmaceutical studies and practices Childhood Cancer Survivors' Quality of Life

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 338, Issue 8, pp. 499-505

DOI: 10.1056/nejm199802193380803

Field-Weighted Citation Impact: 44.14